These findings underscore the need for future studies to incorporate comprehensive molecular and clinical stratification to evaluate glasdegib and other Hh inhibitors in combination with targeted therapies for TP53-mutated AML and MDS. The gene discussed is TP53; the disease is myelodysplastic syndrome.